SLS
SELLAS Life Sciences Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.49
−0.35%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 319.14x
- P/S forward
- 64.22x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 16.86x
- Price / sales
- —
- Price / cash flow
- -81.64x
Enterprise value
- Enterprise value
- $2.2B
- EV / sales
- —
- EV / EBITDA
- -86.01x
- EV / EBIT
- -61.97x
- Market cap
- $2.3B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026